Login to Your Account

The Liver Meeting 2011

In Hepatitis, One Transformation May Soon Be Followed By Next

By Anette Breindl
Science Editor

Tuesday, November 8, 2011

SAN FRANCISCO – Hepatitis C treatment is in a strange space right now. The approval earlier this year of the first two direct-acting antiviral drugs, Incivek (telaprevir, Vertex Pharmaceuticals Inc.) and Victrelis (boceprevir, Merck & Co. Inc.) has brought new options to hepatitis C patients.

The approval of telaprevir and boceprevir has already prompted the American Association for the Study of Liver Diseases to release new treatment guidelines for hepatitis C.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription